Business Context and Reporting Period
Company: Pacific Biosciences of California, Inc. (PACB)
Filing Type: Form 8-K (Current Report)
Date of Report: November 10, 2020
Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Price: $14.25 per share.
- Shares Issued by Company: 6,096,112 shares.
- Shares Sold by Selling Stockholder: 1,304,348 shares (Company received no proceeds from this portion).
- Option Shares Exercised: Underwriters exercised the full option to purchase an additional 914,416 shares from the Company and 195,652 shares from the Selling Stockholder.
- Net Proceeds to Company: Approximately $93.6 million (after underwriting discounts and estimated offering expenses).
- Closing Date: November 13, 2020.
Material Changes and Transaction Structure
The Company entered into an underwriting agreement with Morgan Stanley & Co. LLC and Cowen and Company, LLC. This transaction represents a significant capital raise event distinct from prior periods, as it involves the issuance of new shares and the sale of existing shares by a selling stockholder. The filing does not provide comparative financial metrics (revenue, profit, cash flow) for the period, as this is a transactional report rather than a periodic financial statement.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) regarding the pricing of the offering but does not contain specific forward-looking guidance or operational outlook within the text of this 8-K.
Risks and Contingencies: The Underwriting Agreement includes customary representations, warranties, and indemnification provisions. The filing notes that the agreement is not intended to provide factual information beyond the terms of the transaction and is qualified by the full text of the Underwriting Agreement filed as Exhibit 1.1.
Key Facts for Investor Verification
- Verify the final closing date of November 13, 2020, and the full exercise of the 30-day option by underwriters.
- Confirm the net proceeds of approximately $93.6 million and how these funds are intended to be utilized (not detailed in this specific text).
- Note that the Company received no proceeds from the 1,304,348 shares sold by the Selling Stockholder.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification terms.